Eli Lilly to buy Centessa for $6.3B to get sleep disorder drugnews2026-03-31T11:04:34+00:00March 31st, 2026|Endpoints News|
Eli Lilly to pay $115M upfront to Insilico in AI drug discovery dealnews2026-03-30T14:07:39+00:00March 30th, 2026|Endpoints News|
Kailera plans IPO for Phase 3 obesity drug from Hengruinews2026-03-29T23:05:55+00:00March 29th, 2026|Endpoints News|
Otsuka buys Transcend Therapeutics for $700M upfrontnews2026-03-27T18:21:02+00:00March 27th, 2026|Endpoints News|
Novartis to spend up to $2B on Excellergy and its next-gen Xolair candidatenews2026-03-27T11:21:39+00:00March 27th, 2026|Endpoints News|
Recordati says it’s received a $12B+ takeover bidnews2026-03-26T17:06:08+00:00March 26th, 2026|Endpoints News|
Merck to buy Terns for $6.7B, taking a leukemia drug that could challenge Novartis’ Scemblixnews2026-03-25T10:47:34+00:00March 25th, 2026|Endpoints News|
Apnimed set to exit sleep disorder joint venture with Shionogi for $100M upfrontnews2026-03-24T11:19:25+00:00March 24th, 2026|Endpoints News|
Gilead bets $1.68B upfront on Ouro Medicines’ autoimmune program, with Galapagos expected to pitch innews2026-03-24T10:41:57+00:00March 24th, 2026|Endpoints News|
Merck partners with Flagship startup Quotient to search for genetic clues to IBDnews2026-03-24T10:00:17+00:00March 24th, 2026|Endpoints News|
